RBFC
KRYS icon

Roman Butler Fullerton & Co’s Krystal Biotech KRYS Stock Holding History

Roman Butler Fullerton & Co’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$367K Buy
+1,009
New +$301K 0.09% 213
2026
Q1 		– Sell
-1,125
Closed -$325K – 276
2025
Q4 		$325K Buy
+1,125
New +$237K 0.09% 212
2025
Q2 		– Sell
-3,867
Closed -$654K – 258
2025
Q1 		$654K Buy
+3,867
New +$650K 0.25% 98

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Roman Butler Fullerton & Co's KRYS Position: Q2 2026 in Review

Roman Butler Fullerton & Co opened a new position in Krystal Biotech (KRYS) in Q2 2026: 1,009 shares worth $367K. The stake represents 0.09% of the portfolio and ranks #213 among its holdings. This is a return to the name: Roman Butler Fullerton & Co previously reported a position in KRYS as recently as Q4 2025.

Roman Butler Fullerton & Co first reported a position in KRYS in Q1 2025 and has held it in 3 quarters since. The position peaked at $654K in Q1 2025. 423 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Roman Butler Fullerton & Co held 1,009 shares of Krystal Biotech worth $367K as of Q2 2026.
  • Krystal Biotech was a new Roman Butler Fullerton & Co position in Q2 2026.
  • Krystal Biotech made up 0.09% of Roman Butler Fullerton & Co's portfolio in Q2 2026, its #213 holding.
  • Roman Butler Fullerton & Co first reported a position in Krystal Biotech in Q1 2025 and has held it in 3 quarters since.
  • Roman Butler Fullerton & Co's Krystal Biotech position peaked at $654K in Q1 2025.
  • 423 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Roman Butler Fullerton & Co's 13F filing for Q2 2026, filed 6 Aug 2026.